2022
Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
Gimeno JR, Olivotto I, Rodríguez AI, Ho CY, Fernández A, Quiroga A, Espinosa MA, Gómez‐González C, Robledo M, Tojal‐Sierra L, Day SM, Owens A, Barriales‐Villa R, Larrañaga JM, Rodríguez‐Palomares J, González‐del‐Hoyo M, Piqueras‐Flores J, Reza N, Chumakova O, Ashley EA, Parikh V, Wheeler M, Jacoby D, Pereira AC, Saberi S, Helms AS, Villacorta E, Gallego‐Delgado M, de Castro D, Domínguez F, Ripoll‐Vera T, Zorio‐Grima E, Sánchez‐Martínez J, García‐Álvarez A, Arbelo E, Mogollón MV, Fuentes‐Cañamero M, Grande E, Peña C, Monserrat L, Lakdawala NK, Muñoz‐Esparza C, García‐Pinilla J, Robles‐Mezcua A, Moreno‐Flores M, Peña M, Merlo M, Cubillo D, Climent‐Payá V, Dankovtseva E, Vilela A, García‐Pavía P, Casas G. Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure 2022, 9: 2189-2198. PMID: 36255281, PMCID: PMC9288745, DOI: 10.1002/ehf2.13964.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionVentricular outflow tract obstructionOutflow tract obstructionRisk of mortalityHypertrophic cardiomyopathySARS-CoV-2HCM patientsSystolic impairmentTract obstructionOdds ratioBaseline New York Heart Association classNew York Heart Association classLeft ventricular outflow tract obstructionControl groupPresence of HCMBaseline functional classInternational multicentre registryVentricular systolic impairmentSevere clinical courseMulticentre registryNew onsetRespiratory failureAdverse eventsICU careAssociation class
2021
Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction
Ozaki AF, Krumholz HM, Mody FV, Tran TT, Le QT, Yokota M, Jackevicius CA. Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction. Circulation Cardiovascular Quality And Outcomes 2021, 14: e007665. PMID: 34465124, DOI: 10.1161/circoutcomes.120.007665.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanSacubitril/valsartan useInsurance plan typeReduced ejection fractionHeart failureEjection fractionValsartan useCommercial plansNew York Heart Association classPA criteriaReduced ejection fraction patientsReduced ejection fraction populationPlan typeEjection fraction patientsMedicare plansEjection fraction populationCross-sectional studyProportion of plansPrescription copaymentsAssociation classCopayment amountPrimary outcomeClinical outcomesPlan populationMore prescriptions
2020
Rest-activity rhythms, daytime symptoms, and functional performance among people with heart failure
Jeon S, Conley S, Redeker NS. Rest-activity rhythms, daytime symptoms, and functional performance among people with heart failure. Chronobiology International 2020, 37: 1223-1234. PMID: 32588662, PMCID: PMC7529895, DOI: 10.1080/07420528.2020.1779280.Peer-Reviewed Original ResearchConceptsRest-activity rhythmStable heart failureHeart failureDaytime symptomsCircadian quotientPoorer New York Heart Association classNew York Heart Association classHF disease management programFunctional performanceBetter NYHA classChronic heart failureMinute walk testDisease management programsLess sleep fragmentationHF independentUnattended polysomnographyNYHA classGreater comorbidityAssociation classWalk testIntra-daily variabilityFunctional outcomePhysical functionPoor functionSleep fragmentationStudy Design and Rationale of EXPLORER-HCM
Ho CY, Olivotto I, Jacoby D, Lester SJ, Roe M, Wang A, Waldman CB, Zhang D, Sehnert AJ, Heitner SB. Study Design and Rationale of EXPLORER-HCM. Circulation Heart Failure 2020, 13: e006853. PMID: 32498620, DOI: 10.1161/circheartfailure.120.006853.Peer-Reviewed Original ResearchConceptsNew York Heart Association classLV outflow tract obstructionObstructive hypertrophic cardiomyopathyOutflow tract obstructionPeak oxygen consumptionEXPLORER-HCMTract obstructionAssociation classEnd pointExercise capacityNew York Heart Association functional class IIDynamic LV outflow tract obstructionKansas City Cardiomyopathy QuestionnaireLV outflow tract gradientSymptomatic obstructive hypertrophic cardiomyopathyUnexplained left ventricular hypertrophyOxygen consumptionExploratory end pointsFunctional class IIOutflow tract gradientPlacebo-controlled trialSecondary end pointsPhase 2 studyPhase 3 trialCurrent medical therapy
2019
Baseline Characteristics of the VANISH Cohort
Axelsson Raja A, Shi L, Day SM, Russell M, Zahka K, Lever H, Colan SD, Margossian R, Hall EK, Becker J, Jefferies JL, Patel AR, Choudhury L, Murphy AM, Canter C, Bach R, Taylor M, Mestroni L, Wheeler MT, Benson L, Owens AT, Rossano J, Lin KY, Pahl E, Pereira AC, Bundgaard H, Lewis GD, Vargas JD, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E, Ho CY. Baseline Characteristics of the VANISH Cohort. Circulation Heart Failure 2019, 12: e006231. PMID: 31813281, PMCID: PMC7219518, DOI: 10.1161/circheartfailure.119.006231.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAngiotensin II Type 1 Receptor BlockersBrazilCanadaCardiomyopathy, HypertrophicChildDenmarkDisease ProgressionDouble-Blind MethodFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationPhenotypeRecovery of FunctionSarcomeresTime FactorsTreatment OutcomeUnited StatesValsartanYoung AdultConceptsAngiotensin receptor blockersHypertrophic cardiomyopathyReceptor blockersBaseline characteristicsImaging abnormalitiesPrimary cohortMutation carriersNew York Heart Association class IINew York Heart Association classFunctional class II symptomsOlder ageClass II symptomsNonobstructive hypertrophic cardiomyopathyNormal functional capacityPrevious trialsVentricular wall thicknessPeak oxygen consumptionPlacebo-controlled designCardiac magnetic resonanceGene mutation carriersLate gadolinium enhancementVANISH trialAdvanced diseaseAssociation classVentricular hypertrophy
2018
Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy
Stewart RAH, Szalewska D, Stebbins A, Al-Khalidi HR, Cleland JGH, Rynkiewicz A, Drazner MH, White HD, Mark DB, Roy A, Kosevic D, Rajda M, Jasinski M, Leng CY, Tungsubutra W, Desvigne-Nickens P, Velazquez EJ, Petrie MC. Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. Open Heart 2018, 5: e000752. PMID: 29531766, PMCID: PMC5845417, DOI: 10.1136/openhrt-2017-000752.Peer-Reviewed Original ResearchCoronary artery bypass surgeryIschemic left ventricular dysfunctionLeft ventricular dysfunctionWalk distanceVentricular dysfunctionMedical therapyMED groupFunctional capacityNew York Heart Association classSix-minute walk distanceMin walk distanceCoronary artery bypassArtery bypass surgeryVentricular ejection fractionCoronary artery diseaseArtery bypassBypass surgeryArtery diseaseAssociation classEjection fractionIschemic cardiomyopathySurgical treatmentTreatment allocationDisease trialsPatients
2014
Implant and Clinical Characteristics for Pediatric and Congenital Heart Patients in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry
Jordan CP, Freedenberg V, Wang Y, Curtis JP, Gleva MJ, Berul CI. Implant and Clinical Characteristics for Pediatric and Congenital Heart Patients in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. Circulation Arrhythmia And Electrophysiology 2014, 7: 1092-1100. PMID: 25287482, DOI: 10.1161/circep.114.001841.Peer-Reviewed Original ResearchConceptsNew York Heart Association classPrimary preventionSecondary preventionPediatric patientsAssociation classLEAD patientsGreat vesselsNational Cardiovascular Data Registry Implantable Cardioverter Defibrillator RegistryHigher New York Heart Association classImplantable Cardioverter-Defibrillator RegistryImplantable cardioverter defibrillator implantationNational Cardiovascular Data RegistryImplantable cardioverter-defibrillator indicationsImplantable cardioverter-defibrillator (ICD) proceduresCongenital heart patientsCardioverter-defibrillator implantationStructural heart diseaseHigh rateLead implantsOverall registryVentricle patientsClinical characteristicsDefibrillator implantationCHD typesCommon ventricle
2013
Minimally invasive fibrillating mitral valve replacement for patients with advanced cardiomyopathy: A safe and effective approach to treat a complex problem
Brittain EL, Goyal SK, Sample MA, Leacche M, Absi TS, Papa F, Churchwell KB, Ball S, Byrne JG, Maltais S, Petracek MR, Mendes L. Minimally invasive fibrillating mitral valve replacement for patients with advanced cardiomyopathy: A safe and effective approach to treat a complex problem. Journal Of Thoracic And Cardiovascular Surgery 2013, 148: 2045-2051.e1. PMID: 24332110, PMCID: PMC4050032, DOI: 10.1016/j.jtcvs.2013.10.062.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiomyopathiesDisease-Free SurvivalFemaleHeart Valve Prosthesis ImplantationHospital MortalityHumansKaplan-Meier EstimateMaleMiddle AgedMinimally Invasive Surgical ProceduresMitral ValveMitral Valve InsufficiencyPostoperative ComplicationsRecurrenceRisk FactorsSeverity of Illness IndexStroke VolumeTime FactorsTreatment OutcomeVentricular Dysfunction, LeftVentricular Function, LeftVentricular Function, RightVentricular PressureVentricular RemodelingConceptsLV ejection fractionRecurrent mitral regurgitationRight ventricular systolic pressureVentricular systolic pressureMitral valve replacementSevere mitral regurgitationMitral regurgitationAdvanced cardiomyopathyValve replacementSystolic pressureLV dimensionsThoracic surgeonsNew York Heart Association classLV end-diastolic diameterComposite of deathEnd-diastolic diameterFirst postoperative visitOperative mortalityPostoperative morbidityPostoperative visitAssociation classClinical outcomesEjection fractionDevice insertionPatients
2012
Comparison of pacing algorithms to avoid unnecessary ventricular pacing in patients with sick sinus node syndrome: a single-centre, observational, parallel study
Poghosyan H, Jamalyan S. Comparison of pacing algorithms to avoid unnecessary ventricular pacing in patients with sick sinus node syndrome: a single-centre, observational, parallel study. EP Europace 2012, 14: 1483-1489. PMID: 22628453, DOI: 10.1093/europace/eur415.Peer-Reviewed Original ResearchConceptsSick sinus syndromePacing percentageSingle-centreIncidence of atrial high rate episodesVentricular pacingIncidence of pacemaker syndromeNew York Heart Association classAtrial high rate episodesAtrial pacing percentageVentricular pacing percentagePacing algorithmsSick sinus node syndromeLeft atrial sizeElectronic clinical databaseStatistically significant differenceAtrial sizePaced populationBorderline correlationClinical outcomesPacemaker syndromeRetrospective analysisAmount of VPTreatment strategiesAssociation classClinical trials
2010
Initial Clinical Experience With Extracorporeal Shock Wave Therapy in Treatment of Ischemic Heart Failure
Vasyuk Y, Hadzegova A, Shkolnik E, Kopeleva M, Krikunova O, Iouchtchouk E, Aronova E, Ivanova S. Initial Clinical Experience With Extracorporeal Shock Wave Therapy in Treatment of Ischemic Heart Failure. Congestive Heart Failure 2010, 16: 226-230. PMID: 20887620, DOI: 10.1111/j.1751-7133.2010.00182.x.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionEffect of extracorporeal shock wave therapyIschemic heart failureExtracorporeal shock wave therapyShock wave therapyHeart failureChanges of LVEFCanadian Cardiovascular Society angina classNew York Heart Association classTreatment of ischemic heart failureWave therapySummed rest scoreDobutamine stress echocardiographyVentricular ejection fractionSingle photon emissionSix-minute walk testAngina classEjection fractionStress echocardiographyClinical improvementRest scoreAssociation classTc-99Stable treatmentScore improvement
2005
Sleep and Quality of Life in Stable Heart Failure
Redeker NS, Hilkert R. Sleep and Quality of Life in Stable Heart Failure. Journal Of Cardiac Failure 2005, 11: 700-704. PMID: 16360966, DOI: 10.1016/j.cardfail.2005.07.003.Peer-Reviewed Original ResearchConceptsSelf-reported sleep qualityQuality of lifeMental healthSystolic HFSleep qualityMedical Outcomes Study SF-36 questionnaireNew York Heart Association classPittsburgh Sleep Quality IndexFunctional performanceStable heart failureSystolic HF patientsHeart failure patientsSF-36 questionnaireSleep Quality IndexHF patientsAssociation classFailure patientsHeart failureWrist actigraphSleep continuityPoor sleepNocturnal sleepSleep problemsEffective treatmentSleep duration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply